In summary, morusin has the potential to inhibit human breast cancer cells growth in vitro and in vivo through C/EBPβ and PPARγ mediated adipogenic differentiation and lipoapoptosis induction, it might serve as a novel therapeutic agent for the treatment and/or prevention of human breast cancer, including ER+ breast cancer and TNBC, and need to be investigated further. Here, PPARG is linked to breast cancer.